Code Biotherapeutics Launches with $10 Million in Seed Financing to Develop Therapies for Debilitating Genetic Diseases biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Arcellx, a Gaithersburg, Md.-based clinical-stage biopharmaceutical company advancing a pipeline of adaptive and controllable cell therapies, raised $115m in Series C financing.
The round was co-led by Samsara BioCapital and CAM Capital, joined by new investors Adage, Asymmetry, CaaS Capital, Cambrian Bio, Sixty Degree, Soleus Capital, Surveyor Capital (a Citadel company), Suvretta, and Terra Magnum Capital Partners, and existing investors NEA, Novo Holdings, SR One, Takeda Ventures, LG Tech, and Clough Capital.
The company intends to use the funds to develop CART-ddBCMA, a BCMA-specific CAR-modified T-cell therapy currently in Phase 1 and anticipated to begin a pivotal trial in 2022, and initiate clinical trials evaluating ACLX-001 and ACLX-002, cell therapies derived from its controllable ARC-SparX platform, in multiple myeloma (MM) and acute myelogenous leukemia (AML), respectively.
Search jobs 09-Apr-2021 Palleon Pharmaceuticals Presents Data Suggesting Role of Hypersialylation in Metastatic Melanoma Patients’ Resistance to PD1 Inhibitors
WALTHAM, Mass. (BUSINESS WIRE) Palleon Pharmaceuticals, a company pioneering the field of glycan-mediated immune regulation to treat cancer and inflammatory diseases, today announced the presentation of data supporting the role of hypersialylation in the immune escape of metastatic melanoma at the AACR Annual Meeting held virtually April 10-15, 2021.
The research, conducted in collaboration with Massachusetts General Hospital, used Palleon’s HYDRA technology to quantify immunosuppressive sialoglycans of melanoma tumor samples. The tumor tissue had been surgically removed from patients with stage IV melanoma (n=54) who had had zero to four prior rounds of immunotherapy treatment, prior to their initiation of treatment with a PD1 inhibitor. Hypersialylation of tumor cell-sur
April 1, 2021
By Bio-IT World Staff
April 1, 2021 | New investment funds for late-stage companies and public health. Next-gen genomic medicines and single-cell multiomics get cash, and PatientsLikeMe raises a new round of funding to expand.
$969M Investment Fund for Early to Late-Stage Companies
Foresite Capital, a multi-stage healthcare and life sciences investment firm, has announced its fifth and largest fundraise with $969 million in capital commitments, significantly oversubscribed above its original target. The offering comprises Foresite Capital Fund V, L.P. and Foresite Capital Opportunity Fund V, L.P. With these new funds, Foresite Capital is investing in emerging healthcare and life sciences companies at all stages that are solving some of the biggest inefficiencies and pain points of the $10 trillion global healthcare market. Foresite Capital now has ~$4 billion in assets under management. Press release.
RESEARCH TRIANGLE PARK –StrideBio, an emerging startup focusing on gene therapies, is gearing up for more growth after closing on a big $81.5 million round of venture capital.
Backed by Hatteras Venture Partners in Durham, StrideBio announced the new, second round of cash early Tuesday. The round was oversubscribed, the company says.
In 2018, StrideBio raised nearly $16 million in an oversubscribed first round of funding.
The new funding comes after StrideBio struck a $48 million licensing deal with rare disease drugmaker Sarepta Therapeutics in 2019.
Sapan Shah, a 20-year life science industry veteran, was named StrideBio’s CEO that same year.
“We are very pleased to receive such tremendous support from these top-tier healthcare investors and appreciate the confidence they have placed in our entire team,”Shah said of the new funding. “With this additional funding secured we will be able to translate next generation gene therapies enabled by our lead engineered capsid